Return-path: <bounce-18416124_HTML-982008319-36141554-10831468-448@bounce.broadcastemail.asco.org>
Envelope-to: info@seeinindia.com
Delivery-date: Wed, 03 Jun 2015 02:03:36 +0000
Received: from mta.broadcastemail.asco.org ([64.132.92.206]:59127)
	by bh-in-11.webhostbox.net with esmtp (Exim 4.85)
	(envelope-from <bounce-18416124_HTML-982008319-36141554-10831468-448@bounce.broadcastemail.asco.org>)
	id 1Yzy1n-000jB0-6J
	for info@seeinindia.com; Wed, 03 Jun 2015 02:03:36 +0000
Received: by mta.broadcastemail.asco.org id hdpg7e163hsl for <info@seeinindia.com>; Tue, 2 Jun 2015 20:02:56 -0600 (envelope-from <bounce-18416124_HTML-982008319-36141554-10831468-448@bounce.broadcastemail.asco.org>)
From: "Daily News" <dailynews@asco.org>
To: <info@seeinindia.com>
Subject: =?UTF-8?B?VmlldyBUdWVzZGF54oCZcyBIaWdobGlnaHRzIG9mIHRoZSBEYXkg?=
 =?UTF-8?B?VmlkZW8gZnJvbSB0aGUgMjAxNSBBU0NPIEFubnVhbCBNZWV0aW5n?=
Date: Tue, 02 Jun 2015 20:02:55 -0600
List-Unsubscribe: <mailto:leave-fc5015787165027c77101f2d205921-fe271d7877640475761579-fe621776746005787010-fe6015707d670579731c-ff5f10747d@leave.broadcastemail.asco.org>
MIME-Version: 1.0
x-job: 10831468_36141554
Message-ID: <61a0e16c-5e0c-4667-adac-2a0406d82100@xtinmta199.xt.local>
Content-Type: multipart/alternative;
	boundary="nvo4NTgnHCpY=_?:"
X-Authenticated_sender: 

This is a multi-part message in MIME format.

--nvo4NTgnHCpY=_?:
Content-Type: text/plain;
	charset="us-ascii"
Content-Transfer-Encoding: 7bit

To view this email as a web page, go to the link below, or copy and paste it into your browser's address window.
http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea0ceaec995cc4a4417cb7f68b230f4776ba27287a58f7eee3d027f1c74c313e91bASCO
http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea0b9205811657c1ee16bbe40d61ef65d51079d1e8f27cac92c12ffbe9ddc958169 
Advertisement 
http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea0b9205811657c1ee16bbe40d61ef65d51079d1e8f27cac92c12ffbe9ddc958169 

 

http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea0307f4392798a33de03f5122a6fc737a33cdf4af343d306711034d73a7a53a8cd 

http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea03b0cd66f9ce06cc4835e42a179d5007c27bcde5ec7e952219302598c430f3b55 

http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea03b0cd66f9ce06cc4835e42a179d5007c27bcde5ec7e952219302598c430f3b55 
View Tuesday's Highlights of the Day Video 
 

Breast Cancer

Dr. Eric P. Winer 


Developmental Therapeutics - Immunotherapy

Dr. Ian D. Davis 


Genitourinary (Nonprostate) Cancer 

Dr. Peter Albers 


Gynecologic Cancer

Dr. Kunle Odunsi


Head and Neck Cancer 

Dr. Quynh-Thu Le


Sarcoma 

Dr. Jonathan C. Trent


Tumor Biology 

Dr. Mark M. Moasser


 


Educational Highlights from Today's Sessions 


2015 ASCO Educational Book Articles:

	- 
http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc7648bf721bcb70add45d6b9729703f5b50a73309c86b4861087d2fd70fbadb0d6 

Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?
  - Manisha Bhutani, MD;
Ola Landgren, MD, PhD; and
Saad Z. Usmani, MD, FACP 

	- 
http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc73bbbda48e62b472468892015425ab08f45dc031517d3378283943e0029d33dba 

Assuring Quality Cancer Survivorship Care: We've Only Just Begun
  -Deborah K. Mayer, PhD, RN, AOCN, FAAN;
Charles L. Shapiro, MD;
Paul Jacobson, MD; and
Mary S. McCabe, RN, MA 
	- 
http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc7ee19f8df02485fdd4dbc591281baf931d27748846e23e27bcf2f966afdb9ad28 

Immunotherapeutic Approaches in Prostate Cancer: Combinations and Clinical Integration
  - Susan F. Slovin, MD, PhD, FACP
	- 
http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc7754af683e0a8d0bb155fa96c877cf76466d4a8eb9cd97644cc117f56c70d5275 

The Spectrum of Neuroendocrine Tumors: Histologic Classification, Unique Features and Areas of Overlap
  -David S. Klimstra, MD;
Himisha Beltran, MD;
Rogerio Lilenbaum, MD; and
Emily K. Bergsland, MD 
	- 
http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc7e42da2e78233d2383cdfb33ec6f435b5a0901da59df64a7f60ec3c35bd0a2c33 

Making Sense of Current and Emerging Therapies in Pancreatic Cancer: Balancing Benefit and Value
  -Daniel H. Ahn, DO;
Andrew H. Ko, MD;
Neal J. Meropol, MD, FASCO; and
Tanios S. Bekaii-Saab, MD 

http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc733e151dfe6192eddf11770e872b822d03abde57d7979e1904b751df6a5d7b42f 
Read more from the  2015 ASCO Educational Book » 

 

http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc7d2d7d8c8a18f59078a949156c168c1c58daf01b8fb68c671d2a29bae8b5976d9 
Germ-Line, Other Actionable Mutations Reported with Next-Generation Sequencing 

http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc7d2d7d8c8a18f59078a949156c168c1c58daf01b8fb68c671d2a29bae8b5976d9 
 
With continued advances in next-generation sequencing, germ-line mutations are increasingly being identified. The significance of these findings was a focus of the Clinical Science Symposium "A Tale of Two Genomes: Interpreting Somatic and Germ-Line Sequencing Results Together."


http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc7d2d7d8c8a18f59078a949156c168c1c58daf01b8fb68c671d2a29bae8b5976d9 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc797ebefd375e71b2d8cba7f628b3b0f42d50954920a35d9638f93477375e0dd95 
 
http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc797ebefd375e71b2d8cba7f628b3b0f42d50954920a35d9638f93477375e0dd95 
Phase III MARIANNE Trial Results 

Dr. Paul Anthony Ellis (pictured) presented results of the phase III MARIANNE trial, which showed that T-DM1 treatment resulted in noninferior, but not superior, PFS compared with trastuzumab plus a taxane in patients with locally advanced or metastatic HER2-positive breast cancer. 


http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc797ebefd375e71b2d8cba7f628b3b0f42d50954920a35d9638f93477375e0dd95 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc7af1589dceae50967fc734d79db3238da25aeac29e4fb263ac2a99dd51c3d0515 
 
http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc7af1589dceae50967fc734d79db3238da25aeac29e4fb263ac2a99dd51c3d0515 
Genomic Scarring Predicts Rucaparib Activity in Ovarian Cancer 

Results of the phase II ARIEL2 trial signify a breakthrough in identifying a broader group of patients with ovarian cancer who stand to benefit from inhibitors targeting the PARP family of proteins involved in DNA repair, according to results presented by Dr. Iain A. McNeish (pictured) (Abstract 5508).


http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc7af1589dceae50967fc734d79db3238da25aeac29e4fb263ac2a99dd51c3d0515 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=1795f285f9c1dfc768adb2447eef515da084e9e636cbd2f45380781591e5f2abe7efa8fd5ab0b8e7 
ASCO Daily News Home
http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea0307f4392798a33de03f5122a6fc737a33cdf4af343d306711034d73a7a53a8cd 
 | 
http://click.broadcastemail.asco.org/?qs=43791e0133ae2ad8ea5c77bb4d28e34d6540db7e02f1c2832f2b090ae2df9761c80875bb659317da 
Session Coverage  | 
http://click.broadcastemail.asco.org/?qs=43791e0133ae2ad8c38dcc86c95f841ff52c709a8defd4bacdebfa083f2512ecd73a51414455db7a 
Expert Editorials 

http://click.broadcastemail.asco.org/?qs=43791e0133ae2ad8d1ac68e53cb626d6d78caf18164d401488405093a856429a824a1cf45bdede25 
Grants and Awards  | 
http://click.broadcastemail.asco.org/?qs=43791e0133ae2ad8c489e673d11c74b7eb7930d44d8855befad222b38317a3865b54258d4e3fd87a 
am.asco.org 

Connect with us:
http://click.broadcastemail.asco.org/?qs=43791e0133ae2ad8721c3d2a44fab77fab27a54898fdc3692b131a835026390c2a3cb15c828259dd 

http://click.broadcastemail.asco.org/?qs=43791e0133ae2ad891172b9569b83e322449fd1a4f97b1226c4a73e7a1b0fea6db0598bb72d851e0 

http://click.broadcastemail.asco.org/?qs=43791e0133ae2ad8fb7f3f7f07fd0733c1192c435ef3c0a4814a40e4dbd408346f89e1466caee48a 

http://click.broadcastemail.asco.org/?qs=43791e0133ae2ad88dad53a35e1a45202eef22eed9593d321a84801d10b4590d703825c9eaa2d0b7 
Forward to a Colleague 
http://click.broadcastemail.asco.org/?qs=43791e0133ae2ad88dad53a35e1a45202eef22eed9593d321a84801d10b4590d703825c9eaa2d0b7 

 

http://click.broadcastemail.asco.org/?qs=43791e0133ae2ad8519aaca8901cf6db5019219173d0a1a1375a16280360181d34018dc0cfccd03a 
Advertisement 

http://click.broadcastemail.asco.org/?qs=43791e0133ae2ad8e9068c62303061d3fb545197cce3dbe0ddbbab1613fa80a8657f0db5a6cd970e 

 Advertisement








You are receiving this email because you have an existing relationship
with ASCO.  Visit your personalized 
http://click.broadcastemail.asco.org/?qs=575a298ffee7da4653dab8f2e58d03bc7eb9f63fc747a45e1806e6ab16b8dc8f973f6b7865526132 
Preference Center  to unsubscribe or to select
your preferences for receiving ASCO promotional email.  Please do
not reply to this email.  

This email was sent by: American Society of Clinical Oncology

2318 Mill Road, Suite 800 Alexandria, VA,
22314, USA



--nvo4NTgnHCpY=_?:
Content-Type: text/html;
	charset="us-ascii"
Content-Transfer-Encoding: 7bit

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<div style="display:block;width:100%;text-align:center;font-family: Verdana, sans-serif;font-size:10px;color:#444444;padding:8px 0;margin:auto;">
	To view this email as a web page, go   <a href="http://click.broadcastemail.asco.org/?qs=b12f8b079700b5e0b136077d51529d98fb7d87d85c55d5d147ee3302adcf6da9a84b8f457fdcecf5" > here</a>.
</div><!DOCTYPE html>
<html lang="en">

<head>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <title>ASCO</title>

    <style>
        
        body {margin:0; padding:0; -webkit-text-size-adjust:none; -ms-text-size-adjust:none;} img{line-height:100%; outline:none; text-decoration:none; -ms-interpolation-mode: bicubic;} a img{border: none;} #backgroundTable {margin:0; padding:0; width:100% !important; } a, a:link{color:#318786; text-decoration: none;} table td {border-collapse:collapse;} span {color: inherit; border-bottom: none;} span:hover { background-color: transparent; }

    </style>
</head><body style="background: #d8d8d8;font-family:Arial, Helvetica, sans-serif; font-size:1em;">


    <table id="backgroundTable" width="100%" cellspacing="0" cellpadding="0" border="0" style="background:#d8d8d8;">
        <tr>
            <td class="body" align="center" valign="top" style="background:#d8d8d8;" width="100%">
                <table cellpadding="0" cellspacing="0">
                    <tr>
                        <td class="banner" width="826" align="center" style="background: #d8d8d8; padding-top: 16px;">
                            <table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><div style="text-align: center;">

</div>
<div style="text-align: center;"><a href="http://click.broadcastemail.asco.org/?qs=4608e68001a5ac886124e0da11c029dcc095fdbbffbb259643481fe76badad1cbddc015214968391" title="http://ad.doubleclick.net/ddm/clk/288203934;115218221;x"  ><img src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/TafMek_MAF-1115456_728x90.jpg" title="TafMek_MAF-1115456_728x90" alt="TafMek_MAF-1115456_728x90" border="0" width="728" height="90" style="width: 728px; height: 90px; border-color: #000000; margin: 0px;" /></a></div><div style="text-align: center;">Advertisement&nbsp;</div><a href="http://click.broadcastemail.asco.org/?qs=4608e68001a5ac886124e0da11c029dcc095fdbbffbb259643481fe76badad1cbddc015214968391" title="http://ad.doubleclick.net/ddm/clk/288203934;115218221;x"  >
<br /></a></td></tr></table></td></tr></table>&nbsp;
                        </td>
                    </tr>
                    <tr>
                       
                    </tr>
                    <tr>
                        <td class="main" width="826" align="center">
                            <table cellpadding="0" cellspacing="0">
	<tr>
        <td class="header" width="826" align="left">
            <table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><div style="text-align: center;">
<a href="http://click.broadcastemail.asco.org/?qs=4608e68001a5ac8877844a88f6afab62a291fb1134543a0047fd3da57cc38ec37b83a31d8fda79fb" title="AM Daily News"  ><img width="826" height="115" border="0" alt="NNB banner" title="NNB banner" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/NNB+banner.png" style="width: 826px; height: 115px; border-color: #000000; margin: 0px;" /></a>
</div>
<div style="text-align: center;">
</div></td></tr></table></td></tr></table>
        </td>
    </tr>
    <tr>
    	<td class="subheader" width="826" align="left">
    		
    	</td>
    </tr>
    <tr>
    	<td width="826" style="background: #d8d8d8;">
    		<table cellpadding="0" cellspacing="0">
    			<tr>
    				<td style="padding: 16px;">
    					<table cellpadding="0" cellspacing="0">
    						<tr>
    							<td width="618" valign="top">
    								<table cellpadding="0" cellspacing="0">
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<a href="http://click.broadcastemail.asco.org/?qs=4608e68001a5ac8897d421e7f779537d250463edd66bf2ba05d7752fb419cda1c302d7750d84d529" title=" Highlights of the Day Session III "  ><img width="618" height="200" style="display: block; border: 0px none; width: 618px; height: 200px; margin: 0px;" alt="HOD_1x" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/HOD_III.JPG" title="HOD_1x" dontmaintainaspect="true" thid="5f073c7e-e17d-4c44-9d8d-8dd177895bea" /></a>
			</td>
		</tr>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;"><a title="Highlights of the Day Session III" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=4608e68001a5ac8806aeb8e0976ff53f9f46df36bf61bff553e7cbb1dfc5ed5a3b3677a3e0302958"  >View Tuesday's Highlights of the Day Video 
									</a></td>
								</tr>
								<tr>
									<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
									<p>
									<b>Breast Cancer</b><br />
									Dr. Eric P. Winer 
									</p>
									<p>
									<b>Developmental Therapeutics - Immunotherapy</b><br />
									Dr. Ian D. Davis 
									</p>
									<p>
									<b>Genitourinary (Nonprostate) Cancer </b><br />
									Dr. Peter Albers 
									</p>
									<p>
									<b>Gynecologic Cancer</b><br />
									Dr. Kunle Odunsi
									</p>
								
									<p>
									<b>Head and Neck Cancer </b><br />
									Dr. Quynh-Thu Le
									</p>
									<p>
									<b>Sarcoma </b><br />
									Dr. Jonathan C. Trent
									</p>
									<p>
									<b>Tumor Biology </b><br />
									Dr. Mark M. Moasser
									</p>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table>
<br /></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
									Educational Highlights from Today's Sessions 
									</td>
								</tr>
								<tr>
									<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
									<p>
									<font size="3"><i>2015 ASCO Educational Book</i> Articles:</font>
									</p>
									<ul>
										<li><a href="http://click.broadcastemail.asco.org/?qs=4608e68001a5ac88977c5c51867680c163065a6ba1cbdd29e15b0e31acef6210f978aa5cfaa27b03" title=" Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?" style="color: #318786; text-decoration: none;"  >
										Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?
										</a> -   Manisha Bhutani, MD;
										Ola Landgren, MD, PhD; and
										Saad Z. Usmani, MD, FACP <br />
										</li>
										<li><a href="http://click.broadcastemail.asco.org/?qs=4608e68001a5ac88178ad833398a204b284b94eab9e15ef1a13a357513121b0f675e9f3f8158e371" title="Assuring Quality Cancer Survivorship Care: We've Only Just Begun" style="color: #318786; text-decoration: none;"  >
										Assuring Quality Cancer Survivorship Care: We've Only Just Begun
										</a> -  Deborah K. Mayer, PhD, RN, AOCN, FAAN;
										Charles L. Shapiro, MD;
										Paul Jacobson, MD; and
										Mary S. McCabe, RN, MA </li>
										<li><a href="http://click.broadcastemail.asco.org/?qs=4608e68001a5ac88975fd04c15e30000e580f9fdceff9d48689ad03652f4205473ac78f38b0da184" title=" Immunotherapeutic Approaches in Prostate Cancer: Combinations and Clinical Integration" style="color: #318786; text-decoration: none;"  >
										Immunotherapeutic Approaches in Prostate Cancer: Combinations and Clinical Integration
										</a> - Susan F. Slovin, MD, PhD, FACP</li>
										<li><a href="http://click.broadcastemail.asco.org/?qs=4608e68001a5ac88ff25696bcaf59f2c265f415ed771351d198bf22a592f998aa48c3986291fa556" title=" The Spectrum of Neuroendocrine Tumors: Histologic Classification, Unique Features and Areas of Overlap" style="color: #318786; text-decoration: none;"  >
										The Spectrum of Neuroendocrine Tumors: Histologic Classification, Unique Features and Areas of Overlap
										</a> -  David S. Klimstra, MD;
										Himisha Beltran, MD;
										Rogerio Lilenbaum, MD; and
										Emily K. Bergsland, MD </li>
										<li><a href="http://click.broadcastemail.asco.org/?qs=4608e68001a5ac888786cf4e2da26ebe78090cc25cad609f6093600fd91e0b43438174691a432112" title="Making Sense of Current and Emerging Therapies in Pancreatic Cancer: Balancing Benefit and Value" style="color: #318786; text-decoration: none;"  >
										Making Sense of Current and Emerging Therapies in Pancreatic Cancer: Balancing Benefit and Value
										</a> -  Daniel H. Ahn, DO;
										Andrew H. Ko, MD;
										Neal J. Meropol, MD, FASCO; and
										Tanios S. Bekaii-Saab, MD <br />
										</li>				
									</ul>
									</td>
								</tr>
								<tr>
									<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
									<a href="http://click.broadcastemail.asco.org/?qs=4608e68001a5ac883c671b68cb61e508239847babcfc6cc52bd03359e6c2eff564bbc19ecdd92b4f" style="text-decoration: none; color: #318786;" title="2015 Educational Book">Read more from the <i>2015 ASCO Educational Book </i></a><a style="text-decoration: none; color: #318786;" href="#">&#187;</a>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
									<a   title="Germ-Line, Other Actionable Mutations Reported with Next-Generation Sequencing" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e3fa8b06be54418ffb4092de120d90f53d95203821bf9a894634f542bb511aeb08">Germ-Line, Other Actionable Mutations Reported with Next-Generation Sequencing</a>
									</td>
								</tr>
								<tr>
									<td width="570" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td width="284" valign="top" align="center">
												<a   title="Germ-Line, Other Actionable Mutations Reported with Next-Generation Sequencing" href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e3fa8b06be54418ffb4092de120d90f53d95203821bf9a894634f542bb511aeb08"><img width="250" height="172" style="display: block; border: 0px none; width: 250px; height: 172px; margin: 0px;" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Genomics.jpg" title="Genomics" alt="Genomics" thid="8fa5e0ea-3782-4008-aef0-0c86b1a0aad6" /></a>
												</td>
												<td width="24" style="font-size: 1px;">&nbsp;</td>
												<td width="262" valign="top" align="left">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
With continued advances in next-generation sequencing, germ-line mutations are increasingly being identified. The significance of these findings was a focus of the Clinical Science Symposium "A Tale of Two Genomes: Interpreting Somatic and Germ-Line Sequencing Results Together."
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a   title="Germ-Line, Other Actionable Mutations Reported with Next-Generation Sequencing" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e3fa8b06be54418ffb4092de120d90f53d95203821bf9a894634f542bb511aeb08">Read the Full Story &#187;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="168" valign="top">
									<a href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e3f0213eaeba0de15d801d91cff7bdb3bc025fc4b14c08a11f4b4bc5dd69b3a607" title="Phase III MARIANNE Trial Results"  ><img width="168" height="174" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Ellis_168x174.jpg" alt="Ellis_168x174" style="display: block; border: 0px none; width: 168px; height: 174px; margin: 0px;" title="Ellis_168x174" thid="fa0fb357-b16b-41e6-8f93-2d6dad888b94" /></a>
									</td>
									<td width="24" style="font-size: 1px;">&nbsp;</td>
									<td width="378" valign="top" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
												<a href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e3f0213eaeba0de15d801d91cff7bdb3bc025fc4b14c08a11f4b4bc5dd69b3a607" style="text-decoration: none; color: #318786;" title="Phase III MARIANNE Trial Results"  >Phase III MARIANNE Trial Results</a>
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
Dr. Paul Anthony Ellis (pictured) presented results of the phase III MARIANNE trial, which showed that T-DM1 treatment resulted in noninferior, but not superior, PFS compared with trastuzumab plus a taxane in patients with locally advanced or metastatic HER2-positive breast cancer. 
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
												<a href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e3f0213eaeba0de15d801d91cff7bdb3bc025fc4b14c08a11f4b4bc5dd69b3a607" style="text-decoration: none; color: #318786;" title="Phase III MARIANNE Trial Results"  >Read the Full Story &#187;</a>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="168" valign="top">
									<a href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e3ed846e09e94e2c397cc5dc49ae77662009fee816edd3c4103c8a11de4e24efb1" title="Genomic Scarring Predicts Rucaparib Activity in Ovarian Cancer"  ><img width="168" height="174" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/McNeish_168x174.jpg" alt="McNeish_168x174" style="display: block; border: 0px none; width: 168px; height: 174px; margin: 0px;" title="McNeish_168x174" thid="120490f0-c42c-4fa1-bea9-ac1654ac9ee3" /></a>
									</td>
									<td width="24" style="font-size: 1px;">&nbsp;</td>
									<td width="378" valign="top" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
												<a href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e3ed846e09e94e2c397cc5dc49ae77662009fee816edd3c4103c8a11de4e24efb1" style="text-decoration: none; color: #318786;" title="Genomic Scarring Predicts Rucaparib Activity in Ovarian Cancer"  >Genomic Scarring Predicts Rucaparib Activity in Ovarian Cancer</a>
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
Results of the phase II ARIEL2 trial signify a breakthrough in identifying a broader group of patients with ovarian cancer who stand to benefit from inhibitors targeting the PARP family of proteins involved in DNA repair, according to results presented by Dr. Iain A. McNeish (pictured) (Abstract 5508).
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
												<a href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e3ed846e09e94e2c397cc5dc49ae77662009fee816edd3c4103c8a11de4e24efb1" style="text-decoration: none; color: #318786;" title="Genomic Scarring Predicts Rucaparib Activity in Ovarian Cancer"  >Read the Full Story &#187;</a>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"></td>
    									</tr>
    									<tr>
    										<td width="618"></td>
    									</tr>
									    <tr>
									    	<td width="618"></td>
									    </tr>
									    <tr>
									    	<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="center" style="border-top: 1px solid #ffffff; border-bottom: 2px solid #ffffff; padding: 12px 0px; background: #d2e8e2 none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td align="center" style="font-family: arial,sans-serif; font-size: 16px; font-weight: bold; color: #6a6a6a; line-height: 30px ! important;">
						<a   href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e378b10a8e1373683b963fc544859718182510bac46aea81321e74495f7307efd6" style="text-decoration: none; color: #318786;" title="https://am.asco.org/daily-news"><i>ASCO Daily News</i> Home</a><a href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e3a523583e1e4fde799fcfb8f7b661010f088e109c4514f486aff6812b881baa99ec5c7bb404fad6d0" title="ASCO Daily News Home"  ></a> | <a href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e34a36aaec74807c0e3255bcc6fdd567c2e9fbd83c7dfee2d32ecdc26d4ddabd9d073fc6a75a04c64c" style="text-decoration: none; color: #318786;" title="Session coverage"  >Session Coverage</a> | <a href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e344fe17be95bcb0e3f157b7dbcea02746454ee39391e098bbff5c83c767f91cd2d61f1da8091691ab" style="text-decoration: none; color: #318786;" title="Expert editorials"  >Expert Editorials</a>
						</td>
					</tr>
					<tr>
						<td align="center" style="font-family: arial,sans-serif; font-size: 16px; font-weight: bold; color: #6a6a6a; line-height: 30px ! important;">
						<a href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e3db0aaf30f11cf7e0cb6a4ab54ee5b1776653738c5e8a417695452a669c06933e29d633fa8d522df9" style="text-decoration: none; color: #318786;" title="Grants and Awards"  >Grants and Awards</a> | <a href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e3688afdfcfbca95d715cdade709e88648b1ee235a66882228256b34f9c99b50dfb06c685fcd60acce" style="text-decoration: none; color: #318786;" title="am.asco.org"  >am.asco.org</a>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
									    </tr>
									    <tr>
									    	<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellpadding="0" cellspacing="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="center" style="padding: 12px 0px; background: #efefef;">
			<table cellpadding="0" cellspacing="0">
				<tbody>
					<tr>
						<td style="font-family: arial, sans-serif; font-size: 16px; color: #575757; padding-right: 10px;">Connect with us:</td>
						<td style="padding-right: 10px;"><a href="http://click.broadcastemail.asco.org/?qs=40909ed1d6ee23e350ee8ee89aad81a663d72592e36bb8cdcdc65b7ea930046606250b06d98f1b417760cb49f67fa3ed" title="Twitter"  ><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_11.jpg" style="display: block; border: 0px; width: 32px; height: 32px; margin: 0px;" width="32" height="32" /></a></td>
						<td style="padding-right: 10px;"><a href="http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea0d78ce74b7fac2815ed02f9320daf271ba87ab838d8ce2e3c5d7b5c957fb2e608b6ae3a5737a83564" title="Facebook"  ><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_13.jpg" style="display: block; border: 0px; width: 32px; height: 32px; margin: 0px;" width="32" height="32" /></a></td>
						<td style="padding-right: 10px;"><a href="http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea0556f67eefe577622fe8bccbc6cf3f0b64f2036c670a74f81bee6ab24c5f29efd6dd9e5ca3027dda1" title="Linkedin"  ><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_15.jpg" style="display: block; border: 0px; width: 32px; height: 32px; margin: 0px;" width="32" height="32" /></a></td>
						<td style="padding-right: 20px;"></td>
						<td style="font-family: arial, sans-serif; font-size: 16px; color: #575757; padding-right: 10px;">
						<a href="http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea073fbc651367cc3da171f4149f39f1091c27aeef4eba16ceb217f7abcd913ac94" style="text-decoration: none; color: #318786;">Forward to a Colleague</a>
						</td>
						<td><a href="http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea073fbc651367cc3da171f4149f39f1091c27aeef4eba16ceb217f7abcd913ac94"><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_19.jpg" alt="Email" style="display: block; border: 0px;" /></a></td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
									    </tr>
    								</table>
    							</td>
    							<td width="16" style="font-size: 1px; min-width: 16px;">&nbsp;</td>
    							<td width="160" valign="top">
    								<table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><p align="center">
<a   title="http://ad.doubleclick.net/ddm/clk/288203932;115216566;f" href="http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea0fc404c348e9d28fb3a5e0f6be75937da1e033a77a74b6749f7adfa2ae3ee79cc"><img width="160" height="600" border="0" style="width: 160px; height: 600px; border-color: #000000; margin: 0px;" alt="TafMek_MAF_1115456_160x600" title="TafMek_MAF_1115456_160x600" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/TafMek_MAF_1115456_160x600.jpg" /></a><span style="text-align: center;">Advertisement&nbsp;</span><br>
</p></td></tr></table></td></tr></table>
    							</td>
    						</tr>
    					</table>
    				</td>
    			</tr>
    		</table>
    	</td>
    </tr>
    <tr>
    	<td class="disclaimer" width="826" align="center">
    		<table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><div align="center"><a   title="Conquer Cancer Foundation" href="http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea0725e1a1d89b829e4172b7656564e74b079066fbf7757fd7e11217ab70d830b94">
<img width="728" height="90" border="0" style="width: 728px; height: 90px; border-color: #000000; margin: 0px;" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/033566_ascocf_HCP_BannerAds_Type_728x90_lo1op2.jpg" title="033566_ascocf_HCP_BannerAds_Type_728x90_lo1op2" alt="033566_ascocf_HCP_BannerAds_Type_728x90_lo1op2" /></a><br /> Advertisement</div></td></tr></table></td></tr></table>
    	</td>
    </tr>
</table>
                        </td>
                    </tr>
                    <tr>
                      
                                            </tr>
                                        </table>
                                    </td>
                                </tr>
                            </table>
                        </td>
                    </tr>
                </table>
            </td>
        </tr>
    </table>

    <!-- Exact Target tracking code -->
    <img src="http://click.broadcastemail.asco.org/open.aspx?ffcb10-fe621776746005787010-fdc61574706c037c7112727664-fe6015707d670579731c-fe6415787165027c7710-fe271d7877640475761579-ff5f10747d" width="1" height="1">

</body>
 <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<title></title>
</head><body style="background: #d8d8d8;font-family:Arial, Helvetica, sans-serif; font-size:1em;">
<body>


<div width="850" style="margin-left: auto; margin-right: auto; width: 850px; text-align: left;">

You are receiving this email because you have an existing relationship
with ASCO.&nbsp; Visit your personalized <a
href="http://click.broadcastemail.asco.org/?qs=ba2edc5f472adea0fbbba6957a6f949b4d85ccc00383816e3078954caaf25999bd4da0b714818a84"
target="_blank">Preference Center</a> to unsubscribe or to select
your preferences for receiving ASCO promotional email.&nbsp; Please do
not reply to this email.&nbsp; <br>
This email was sent by: American Society of Clinical Oncology<br>
2318 Mill Road, Suite 800 Alexandria, VA,
22314, USA<br></div>
</body>
</body>
</html>

--nvo4NTgnHCpY=_?:--

